This invention relates to aspartyl protease inhibitors, pharmaceutical compositions comprising said compounds, their use in the treatment of cardiovascular diseases, cognitive and neurodegenerative diseases, and their use as {HEAD ~ inhibitors} of the Human Immunodeficiency Virus, plasmepsins, {TAIL ~ cathepsin D} and protozoal enzymes 
This invention relates to aspartyl protease inhibitors , pharmaceutical compositions comprising said compounds , their use in the treatment of cardiovascular diseases , cognitive and neurodegenerative diseases , and their use as { HEAD ~ inhibitors } of the Human Immunodeficiency Virus , plasmepsins , { TAIL ~ cathepsin D } and protozoal enzymes
OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH OTH HEAD HEAD HEAD HEAD HEAD REL OTH OTH OTH OTH OTH OTH OTH TAIL TAIL TAIL TAIL TAIL TAIL OTH OTH OTH